The neuronal pentraxin-2 pathway is an unrecognized target in human neuroblastoma, which also offers prognostic value in patients

Cancer Research

Volumn 75, Issue 20, 2015, Pages 4265-4271

  Bartolini, Alice ^a   Di Paolo, Daniela ^b   Noghero, Alessio ^a   Murgia, Daniele ^b   Sementa, Angela R ^b   Cilli, Michele ^c   Pasqualini, Renata ^d,e   Arap, Wadih ^d,e   Bussolino, Federico ^a,f   Ponzoni, Mirco ^b   Pastorino, Fabio ^b   Marchiò, Serena ^a,f  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEURONAL PENTRAXIN 2; NEURONAL PENTRAXIN RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; PENTRAXIN; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; LIGAND; MONOCLONAL ANTIBODY; NERVE PROTEIN; NEURONAL PENTRAXIN; PEPTIDE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; MICE; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEUROBLASTOMA; PEPTIDES; PROGNOSIS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945552075     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0649     Document Type: Article

References (20)

1. Maris JM. Recent advances in neuroblastoma. New Eng J Med 2010;362: 2202-11.
2. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84.
3. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 2014;26:414-27.
4. Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, et al. Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res 2012;18:1588-97.
5. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-71.
6. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013;45: 12-7.
7. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008;68:9735-45.
8. Bresler SC, Weiser DA, Huwe PJ, Partk JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26: 682-94.
9. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009;15:3244-50.
10. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012;18:2780-90.
11. Pastorino F, Brignole C, Loi M, Di Paolo D, Di Fiore A, Perri P, et al. Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. Front Oncol 2013;3:190.
12. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. New Engl J Med 2010;363:1324-34.
13. Marchiò S, Soster M, Cardaci S, Muratore A, Bartolini A, Barone V, et al. A complex of alpha6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. EMBO Mol Med 2012;4:1156-75.
14. Loi M, Di Paolo D, Soster M, Brignole C, Bartolini A, Emionite L, et al. Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. J Control Release 2013;170:233-41.
15. Hsu YC, Perin MS. Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. Genomics 1995;28: 220-7.
16. von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res 2014;74:4796-810.
17. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63:7400-9.
18. Dodds DC, Omeis IA, Cushman SJ, Helms JA, Perin MS. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calciumbinding protein 49. J Biol Chem 1997;272:21488-94.
19. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.
20. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E. Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977;74:739-43.